Advisor Group Inc. boosted its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 33.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 206,213 shares of the biopharmaceutical company’s stock after acquiring an additional 51,686 shares during the period. Advisor Group Inc.’s holdings in Bristol-Myers Squibb were worth $10,720,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently made changes to their positions in the business. LSV Asset Management lifted its position in shares of Bristol-Myers Squibb by 317.2% during the third quarter. LSV Asset Management now owns 37,131 shares of the biopharmaceutical company’s stock worth $2,305,000 after purchasing an additional 28,231 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Bristol-Myers Squibb by 144.4% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 11,640 shares of the biopharmaceutical company’s stock worth $723,000 after purchasing an additional 6,878 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Bristol-Myers Squibb by 9.9% during the third quarter. Crossmark Global Holdings Inc. now owns 38,557 shares of the biopharmaceutical company’s stock worth $2,394,000 after purchasing an additional 3,470 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Bristol-Myers Squibb by 1.6% during the third quarter. Bank of New York Mellon Corp now owns 17,123,173 shares of the biopharmaceutical company’s stock worth $1,063,006,000 after purchasing an additional 277,927 shares in the last quarter. Finally, Kavar Capital Partners LLC acquired a new position in shares of Bristol-Myers Squibb during the third quarter worth $250,000. 73.14% of the stock is owned by hedge funds and other institutional investors.
BMY stock opened at $49.19 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.61 and a quick ratio of 1.50. Bristol-Myers Squibb Co has a 1-year low of $44.30 and a 1-year high of $66.99. The firm has a market cap of $80.98 billion, a price-to-earnings ratio of 12.36, a price-to-earnings-growth ratio of 2.54 and a beta of 0.81.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The firm had revenue of $5.97 billion during the quarter, compared to analyst estimates of $5.95 billion. During the same quarter in the previous year, the firm earned $0.68 earnings per share. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. Equities research analysts predict that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $1.64 annualized dividend and a yield of 3.33%. Bristol-Myers Squibb’s payout ratio is 41.21%.
A number of analysts recently issued reports on BMY shares. Morgan Stanley set a $54.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Thursday, December 20th. Credit Suisse Group restated a “hold” rating and issued a $59.00 price target on shares of Bristol-Myers Squibb in a research note on Thursday, December 13th. BMO Capital Markets restated a “buy” rating and issued a $59.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, February 19th. Societe Generale upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a research note on Tuesday, January 15th. Finally, Bank of America set a $53.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Friday, January 25th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $59.59.
ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Holdings Raised by Advisor Group Inc.” was reported by Zolmax and is the property of of Zolmax. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://zolmax.com/investing/bristol-myers-squibb-co-bmy-holdings-raised-by-advisor-group-inc/2978354.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Recommended Story: What is the Quick Ratio?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.